Welcome!

Apache Authors: Carmen Gonzalez, Liz McMillan, Elizabeth White, Pat Romanski, Christopher Harrold

News Feed Item

RBC Life Sciences Reports Second Quarter Results

IRVING, Texas, Aug. 14, 2014 /PRNewswire/ -- RBC Life Sciences, Inc. (OTCQB: RBCL), a provider of proprietary nutritional supplements, and wound care and pain management products, today reported consolidated net sales of $7.9 million for the quarter ended June 30, 2014, an 18% increase over net sales of $6.7 million in the second quarter of 2013. The Company reported a second quarter net loss of $7,000, or $0.00 per share, compared to a net loss of $147,000, or $0.07 per share, for the same quarter last year.  Net sales were $13.6 million for the six months ended June 30, 201, a 10% increase over net sales of $12.4 million in the same period last year.  For the six months ended June 30, 2014 the Company reported a net loss of $385,000, or $0.17 per share, compared to a net loss of $155,000, or $0.07 per share, in the comparable period in 2013.  All per share amounts have been restated to reflect the 1-for-500 reverse stock split and 50-for-1 forward stock split affected on August 9, 2013. 

"The Company has focused in the last few years on expansion in Southeast Asia and promoting our lead product Stem-Kine, a nutritional supplement that has been shown in human clinical studies to enable the body to produce more stem cells.  We are pleased with the increasing sales of Stem-Kine as more and more people become aware of the benefits of autologous stem cells through reports on hundreds of clinical trials being conducted throughout the world," said RBC Life Sciences CEO, Clinton H. Howard.

Mr. Howard continued, "Sales of Nutritional Products through our network of independent Associates increased 64% during the second quarter of 2014 compared with Associate network sales in the same quarter last year.  Sales of Nutritional Products to our foreign licensees increased 3% in the second quarter of this year compared to the same period in 2013.  During the second quarter, we opened our fourth training and distribution center in Southeast Asia located in Jakarta, Indonesia."

About RBC Life Sciences
Through wholly owned subsidiaries,RBC Life Sciences develops, manufactures and markets high-quality nutritional supplements under the RBC Life brand to a growing population of consumers seeking healthy lifestyle and an opportunity to increase their long-term family income. Through its wholly owned subsidiary, MPM Medical, the Company also develops and markets to health care professionals in the United States proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than 30 countries in which the products are distributed. For more information, visit the company's website at www.rbclifesciences.com.

The statements above, other than statements of historical fact, that express a belief, expectation or intention may be forward-looking statements within the meaning of the federal securities laws.  Actual events will be dependent upon a number of factors and risks including, but not limited to, changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange Commission.  Although we believe that the expectations reflected in these forward-looking statements are reasonable, we can give no assurance that such expectations will prove to have been correct.  Further, we specifically disclaim any duty to update any of the information set forth in this press release, including any forward-looking statements.  Forward-looking statements are made based on management's current expectations and beliefs concerning future events and, therefore, involve a number of assumptions, risks and uncertainties.  Management cautions that forward-looking statements are not guarantees, and our actual results could differ materially from those expressed or implied in the forward-looking statements.

For Further Information:
Steven E. Brown, President, CFO
Tel: 972-893-4000
[email protected]


 

RBC Life Sciences, Inc.

Summary Results of Operations

(in thousands, except per share data)

(unaudited)



Quarter Ended June 30,



2014



2013


Net sales

$

7,885



$

6,694


Gross profit

4,122



2,971


Operating income (loss)

33



(198)


Earnings (loss) before income taxes

9



(226)


Provision (benefit) for income taxes

16



(79)


Net loss

(7)



(147)








Loss per share - basic (a)

$

(0.00)



$

(0.07)


Loss per share - diluted (a)

$

(0.00)



$

(0.07)








Weighted average shares outstanding - basic (a)

2,212



2,223


Weighted average shares outstanding - diluted (a)

2,212



2,223









Six Months Ended June 30,



2013



2012


Net sales

$

13,598



$

12,386


Gross profit

7,304



5,944


Operating loss

(459)



(174)


Loss before income taxes

(509)



(232)


Benefit for income taxes

(124)



(77)


Net loss

(385)



(155)








Loss per share - basic (a)

$

(0.17)



$

(0.07)


Loss per share - diluted (a)

$

(0.17)



$

(0.07)








Weighted average shares outstanding - basic (a)

2,212



2,223


Weighted average shares outstanding - diluted (a)

2,212



2,223








(a)

All share and per share amounts have been adjusted to reflect the 1-for-500 reverse stock split and 50-for-1 forward stock split affected on August 9, 2013

 

 

RBC Life Sciences, Inc.

Condensed Consolidated Balance Sheets

(in thousands)

(unaudited)



June 30,



December 31,



2014



2013


Assets






Cash and cash equivalents

$

2,113



$

3,746


Inventories

5,553



5,142


Other current assets

2,030



2,130


Total current assets

9,696



11,018


Other assets

7,048



6,516


Total assets

$

16,744



$

17,534








Liabilities and shareholders' equity






Accounts payable and accrued liabilities

$

3,795



$

2,765


Deferred revenue

2,474



3,678


Other current liabilities

221



212


Total current liabilities

6,490



6,655


Other liabilities

1,628



1,865


Shareholders' equity

8,626



9,014


Total liabilities and shareholders' equity

$

16,744



$

17,534


SOURCE RBC Life Sciences, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

IoT & Smart Cities Stories
The platform combines the strengths of Singtel's extensive, intelligent network capabilities with Microsoft's cloud expertise to create a unique solution that sets new standards for IoT applications," said Mr Diomedes Kastanis, Head of IoT at Singtel. "Our solution provides speed, transparency and flexibility, paving the way for a more pervasive use of IoT to accelerate enterprises' digitalisation efforts. AI-powered intelligent connectivity over Microsoft Azure will be the fastest connected pat...
There are many examples of disruption in consumer space – Uber disrupting the cab industry, Airbnb disrupting the hospitality industry and so on; but have you wondered who is disrupting support and operations? AISERA helps make businesses and customers successful by offering consumer-like user experience for support and operations. We have built the world’s first AI-driven IT / HR / Cloud / Customer Support and Operations solution.
Codete accelerates their clients growth through technological expertise and experience. Codite team works with organizations to meet the challenges that digitalization presents. Their clients include digital start-ups as well as established enterprises in the IT industry. To stay competitive in a highly innovative IT industry, strong R&D departments and bold spin-off initiatives is a must. Codete Data Science and Software Architects teams help corporate clients to stay up to date with the mod...
At CloudEXPO Silicon Valley, June 24-26, 2019, Digital Transformation (DX) is a major focus with expanded DevOpsSUMMIT and FinTechEXPO programs within the DXWorldEXPO agenda. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive over the long term. A total of 88% of Fortune 500 companies from a generation ago are now out of business. Only 12% still survive. Similar percentages are found throug...
Druva is the global leader in Cloud Data Protection and Management, delivering the industry's first data management-as-a-service solution that aggregates data from endpoints, servers and cloud applications and leverages the public cloud to offer a single pane of glass to enable data protection, governance and intelligence-dramatically increasing the availability and visibility of business critical information, while reducing the risk, cost and complexity of managing and protecting it. Druva's...
BMC has unmatched experience in IT management, supporting 92 of the Forbes Global 100, and earning recognition as an ITSM Gartner Magic Quadrant Leader for five years running. Our solutions offer speed, agility, and efficiency to tackle business challenges in the areas of service management, automation, operations, and the mainframe.
The Jevons Paradox suggests that when technological advances increase efficiency of a resource, it results in an overall increase in consumption. Writing on the increased use of coal as a result of technological improvements, 19th-century economist William Stanley Jevons found that these improvements led to the development of new ways to utilize coal. In his session at 19th Cloud Expo, Mark Thiele, Chief Strategy Officer for Apcera, compared the Jevons Paradox to modern-day enterprise IT, examin...
With 10 simultaneous tracks, keynotes, general sessions and targeted breakout classes, @CloudEXPO and DXWorldEXPO are two of the most important technology events of the year. Since its launch over eight years ago, @CloudEXPO and DXWorldEXPO have presented a rock star faculty as well as showcased hundreds of sponsors and exhibitors! In this blog post, we provide 7 tips on how, as part of our world-class faculty, you can deliver one of the most popular sessions at our events. But before reading...
DSR is a supplier of project management, consultancy services and IT solutions that increase effectiveness of a company's operations in the production sector. The company combines in-depth knowledge of international companies with expert knowledge utilising IT tools that support manufacturing and distribution processes. DSR ensures optimization and integration of internal processes which is necessary for companies to grow rapidly. The rapid growth is possible thanks, to specialized services an...
At CloudEXPO Silicon Valley, June 24-26, 2019, Digital Transformation (DX) is a major focus with expanded DevOpsSUMMIT and FinTechEXPO programs within the DXWorldEXPO agenda. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive over the long term. A total of 88% of Fortune 500 companies from a generation ago are now out of business. Only 12% still survive. Similar percentages are found throug...